Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness

Rituximab (375 mg/m(2)) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A(2) receptor (PLA(2)R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine. Between-treatments interval averaged 17...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMJ Case Rep
Главные авторы: Podestà, Manuel Alfredo, Ruggiero, Barbara, Remuzzi, Giuseppe, Ruggenenti, Piero
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035801/
https://ncbi.nlm.nih.gov/pubmed/31980477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232896
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы